BMS

Bristol Myers Squibb Company (doing business as Bristol Myers Squibb, commonly "BMS") is a US multinational biopharmaceutical company headquartered in Princeton, New Jersey. It is publicly traded on the NYSE under the ticker BMY and has no parent company. The business traces to Bristol-Myers (founded 1887) and its 1989 merger with Squibb; it is led by CEO Christopher S. Boerner. Per the company's own key-facts page and its Q4 2024 earnings release, it reported $48.3 billion in 2024 global revenues and $11.2 billion in R&D investment, with roughly 32,500–34,100 employees depending on the source.

Operations. BMS discovers, develops, manufactures and markets branded prescription medicines, with major franchises in oncology (Opdivo/nivolumab, Yervoy), hematology (Revlimid/lenalidomide, Pomalyst/pomalidomide, acquired with Celgene), cardiovascular (Eliquis) and immunology (Orencia, Sotyktu, Zeposia). It is a large operating company, not a patent-assertion entity.

Litigation posture. The tracked data show BMS as a defendant in one case and as plaintiff in none — the profile of an operating company being attacked rather than an NPE asserting an acquired portfolio. The single matter sits in the Southern District of New York, not a plaintiff-friendly venue such as the Eastern District of Texas. Note that this case is an antitrust action in which patent conduct is the factual core, rather than a conventional infringement suit filed by a non-practicing entity.

Notable case. The Cigna Group v. Celgene Corporation et al., No. 1:25-cv-05237-ER (S.D.N.Y., filed June 24, 2025, Judge Edgardo Ramos), names Celgene Corporation and its parent Bristol Myers Squibb. Cigna alleges a Section 2 Sherman Act monopolization scheme around pomalidomide (Pomalyst), claiming patents were procured through fraud on the USPTO, enforced through sham infringement suits, and resolved via "pay-for-delay" reverse payments to generic manufacturers. The 2019 Celgene acquisition (announced at roughly $74 billion) is the context tying the subsidiary's pomalidomide portfolio to BMS. Allegations are unadjudicated; no merits conclusion is implied here.